Tags: myelodysplastic syndromes
Highlights in Myelodysplastic Syndromes From the 62nd American Society of Hematology Annual Meeting and Exposition
A Review of Selected Presentations From the All-Virtual 62nd ASH Meeting and Exposition • December 5-8, 2020 Efficacy and Safety of Luspatercept Treatment in Patients […]
Highlights in Myelodysplastic Syndromes From the 2020 American Society of Clinical Oncology Annual Meeting and the 25th European Hematology Association Congress
A Review of Selected Presentations From the 2020 ASCO Annual Meeting and the EHA25 Congress Clinical Benefit of Luspatercept in Patients With Lower-Risk MDS and […]
Highlights in Myelodysplastic Syndromes From the 61st American Society of Hematology Annual Meeting
A Review of Selected Presentations From the 61st ASH Meeting • December 7-10, 2019 • Orlando, Florida Hematologic Improvement–Neutrophil and–Platelet in the MEDALIST Trial: Multilineage […]
Highlights in Myelodysplastic Syndromes From the 60th American Society of Hematology Annual Meeting
A Review of Selected Presentations From the 60th American Society of Hematology Annual Meeting • December 1-4, 2018 • San Diego, California The MEDALIST Trial: […]
FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Abstract: The fms-like receptor tyrosine kinase-3 (FLT3), which is important for the normal development of hematopoietic stem cells and cells of the immune system, is frequently mutated in patients with acute myeloid leukemia (AML). FLT3 is, therefore, a potential therapeutic target in AML. Recently, FLT3 inhibitors have shown therapeutic activity in AML patients with FLT3 mutations. Sorafenib and sunitinib were the first FLT3 inhibitors to be studied in the clinic and have the most clinically relevant data. Limited data are available for midostaurin (PKC412), lestaurtinib (CEP-701), tandutinib (MLN518), AC220, and KW-2449. It is likely that optimal application of these agents will involve combinations of inhibitors and combinations of inhibitors and chemotherapy, potentially with a mammalian target of rapamycin inhibitor such as everolimus or temsirolimus. This review discusses the theoretical rationale for the use of these agents and summarizes the relevant clinical data.